MX2023005693A - Anticuerpos de cadena pesada que se unen al receptor de folato alfa. - Google Patents

Anticuerpos de cadena pesada que se unen al receptor de folato alfa.

Info

Publication number
MX2023005693A
MX2023005693A MX2023005693A MX2023005693A MX2023005693A MX 2023005693 A MX2023005693 A MX 2023005693A MX 2023005693 A MX2023005693 A MX 2023005693A MX 2023005693 A MX2023005693 A MX 2023005693A MX 2023005693 A MX2023005693 A MX 2023005693A
Authority
MX
Mexico
Prior art keywords
receptor alpha
folate receptor
heavy chain
chain antibodies
antibodies binding
Prior art date
Application number
MX2023005693A
Other languages
English (en)
Inventor
Nathan Trinklein
Katherine Harris
Brian Avanzino
Hannes Kehm
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2023005693A publication Critical patent/MX2023005693A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos de cadena pesada anti-receptor de folato alfa (FOLR1) (por ejemplo, UniAbsTM), junto con métodos para preparar tales anticuerpos, composiciones, incluyendo composiciones farmacéuticas, que comprenden tales anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión del receptor de folato alfa (FOLR1).
MX2023005693A 2020-11-18 2021-11-17 Anticuerpos de cadena pesada que se unen al receptor de folato alfa. MX2023005693A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063115436P 2020-11-18 2020-11-18
PCT/US2021/059701 WO2022109010A1 (en) 2020-11-18 2021-11-17 Heavy chain antibodies binding to folate receptor alpha

Publications (1)

Publication Number Publication Date
MX2023005693A true MX2023005693A (es) 2023-05-29

Family

ID=79024440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005693A MX2023005693A (es) 2020-11-18 2021-11-17 Anticuerpos de cadena pesada que se unen al receptor de folato alfa.

Country Status (17)

Country Link
US (1) US20240002498A1 (es)
EP (1) EP4247498A1 (es)
JP (1) JP2023549851A (es)
KR (1) KR20230110303A (es)
CN (1) CN116615253A (es)
AR (1) AR124084A1 (es)
AU (1) AU2021383743A1 (es)
CA (1) CA3199785A1 (es)
CL (1) CL2023001432A1 (es)
CO (1) CO2023006790A2 (es)
CR (1) CR20230259A (es)
IL (1) IL302670A (es)
MX (1) MX2023005693A (es)
PE (1) PE20231203A1 (es)
TW (1) TW202233684A (es)
UY (1) UY39522A (es)
WO (1) WO2022109010A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
PT2311874T (pt) 2004-07-22 2017-08-25 Univ Erasmus Med Ct Rotterdam Moléculas de ligação
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
JP6061469B2 (ja) 2009-03-10 2017-01-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗ｂｃｍａ抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
DK3221355T3 (da) * 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
SI3221356T1 (sl) * 2014-11-20 2021-01-29 F. Hoffmann-La Roche Ag Bispecifične molekule, ki vežejo antigene in aktivirajo celice T, proti FOLR1 in CD3
KR20190053835A (ko) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 Cd3 결합 항체
CA3034706A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
KR102505681B1 (ko) 2016-09-14 2023-03-06 테네오바이오, 인코포레이티드 Cd3 결합 항체
BR112020016469A2 (pt) * 2018-03-13 2020-12-15 Phanes Therapeutics, Inc. Anticorpos do receptor anti-folato 1 e seus usos

Also Published As

Publication number Publication date
AU2021383743A1 (en) 2023-06-08
KR20230110303A (ko) 2023-07-21
TW202233684A (zh) 2022-09-01
AR124084A1 (es) 2023-02-08
PE20231203A1 (es) 2023-08-17
CA3199785A1 (en) 2022-05-27
EP4247498A1 (en) 2023-09-27
IL302670A (en) 2023-07-01
CL2023001432A1 (es) 2024-01-05
CO2023006790A2 (es) 2023-06-09
JP2023549851A (ja) 2023-11-29
CR20230259A (es) 2023-07-13
WO2022109010A1 (en) 2022-05-27
US20240002498A1 (en) 2024-01-04
CN116615253A (zh) 2023-08-18
UY39522A (es) 2022-06-30

Similar Documents

Publication Publication Date Title
JOP20210253A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
MX2018015271A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
NZ737399A (en) Ccr2 modulators
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
MX2023005693A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2022016342A (es) Union de anticuerpos multiespecificos a bcma.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CR20200322A (es) Anticuerpos de cadena pesada que se unen a cd22
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
MX2022013453A (es) Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX2021005085A (es) Formulacion de anticuerpo.
CR20230507A (es) Anticuerpos anti-il-2r agonistas y métodos de uso
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2023005408A (es) Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina.